Tuesday, Merck & Co Inc (NYSE:MRK) released data from multiple Phase 3 studies evaluating V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the Meeting of the International Society of Pneumonia and Pneumococcal Diseases (ISPPD).
Across the clinical studies presented, V116 was shown to be immunogenic for all 21 serotypes covered by the vaccine in a variety of adult populations, including those who had not previously received a pneumococcal vaccine (pneumococcal vaccine-naïve), those who had previously received a pneumococcal vaccine (pneumococcal vaccine-experienced) and those with an increased risk of pneumococcal disease, including people living with human immunodeficiency virus (HIV).
Related: Merck Highlights Data On New Vaccine, Compares ‘Tolerability And Safety’ To Pfizer’s.
V116 also elicited higher immune responses than the studied comparators for the serotypes unique to V116 in all STRIDE studies ...